High Throughput Screening Market Analysis

High Throughput Screening Market Analysis

To get key market trends

  Download Free Sample

Based on products and services, the high throughput screening market is categorized into consumables, software and services and instruments. The software and services segment held significant share in 2022 and is projected to witness fastest growth with a CAGR of 9.1% over the forecast period. HTS target profiling assays, assay development and testing, data-validation, and storage, and hit validation, among others are key services provided by players operating in the industry. Further, use and adoption of advanced data processing software for automation of different liquid handling systems is a key factor driving the market expansion.
 

Based on technology, the high throughput screening market is segmented into cell-based assays, lab-on-a-chip, label-free technology, and ultra high throughput screening. The cell-based assays segment was valued at around USD 12.6 billion in 2022. This is primarily attributed to the fact that in contrast to traditional biochemical assays, cell-based assays can generate and facilitate more complex biologically relevant data and evaluate compound characteristics simultaneously. Large number of companies are undergoing the transition from 2D-based cell culture to 3D-based cell culture as it offers more approximate physical environment along with accurate results in drug screening studies.
 

Based on application, the high throughput screening market is categorized into biochemical screening, drug discovery, life sciences research, and others. The drug discovery segment is projected to reach over USD 31.3 billion in 2032. HTS method is used to test genomics, combinatorial chemistry, and protein libraries for target identification during the drug discovery process. Development of novel drugs for life threatening conditions, reduction in drug developing timeline, and adoption of ultra HTS technique for faster assay screening are other factors supporting the industry expansion. Moreover, notable penetration of 3D-cell cultures for developing new drug molecule is further boosting the market size.
 

Based on end-use, the high throughput screening market is bifurcated into academic and research institutes, contract research organizations, and pharmaceutical & biotechnology companies. Pharmaceutical and biotechnology firms segment was valued at around USD 16.7 billion in 2022. This is primarily attributed to increasing adoption of HTS technologies in drug discovery process in pharma companies globally. Factors such as need for precise, rapid and faster screening of target molecules during drug development process, adoption of uHTS method for screening of large number of chemical and biomarker libraries generated during the research phase is anticipated to propel the segment progression. Additionally, rise in R&D spending by major pharma and biotech companies worldwide is predicted to contribute to industry development.
 

North America held a dominant market share in the global high throughput screening market and is expected to grow at 7.7% CAGR by 2032. The high industry growth is due to numerous factors such as high disease burden rate, technological advancements, increased R&D spending, and industrial collaboration among key players, etc. Additionally, presence of key market players, increase in the incidence and prevalence of chronic diseases, and growing trend of open innovation model is projected to foster the market outlook.
 

Regional government along with venture capital agencies are actively focusing on increasing the research spending for new and improved drug molecules which in turn will boost the adoption of HTS technology. Surging adoption of HTS methods by generic manufacturers for hit identification and target validation throughout the drug development process will fuel the industry development.